SCHEMBL23740412

SCHEMBL23740412

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4oc5cccc(-n6c7ccccc7c7ccc8ccccc8c76)c5c4c3)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
FYN P06241 1/20 0.34
MAPK3 P27361 1/20 0.34
AHR P35869 1/20 0.34
PAX8 Q06710 1/20 0.34
MAPT P10636 4/20 0.33
HPGD P15428 4/20 0.33
TSHR P16473 4/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 3/20 0.33
HSD17B10 Q99714 3/20 0.33
PLA2G2A P14555 2/20 0.33
PLA2G4A P47712 2/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
PLA2G10 O15496 1/20 0.33
TDP1 Q9NUW8 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24363510 0.99 ABCG2 (0.34) ABCG2CYP1A1CYP1A2FYNMAPK3
SCHEMBL24216768 0.90 PLA2G2A (0.37) CYP1A2MAPTHPGDTSHRALDH1A1
SCHEMBL25627319 0.89 KDM4E (0.35) CYP1A2HPGDALDH1A1KDM4EPLA2G2A
SCHEMBL24848888 0.89 ABCG2 (0.34) ABCG2CYP1A1CYP1A2FYNMAPK3
SCHEMBL24363428 0.89 CYP1A2 (0.38) ABCG2CYP1A1CYP1A2FYNMAPK3
SCHEMBL24216550 0.89 PLA2G2A (0.38) MAPTHPGDTSHRALDH1A1KDM4E
SCHEMBL25953166 0.89 ALDH1A1 (0.36) ABCG2CYP1A1CYP1A2FYNMAPK3
SCHEMBL24215952 0.88 CHEK2 (0.35) AHRMAPTHPGDTSHRALDH1A1
SCHEMBL25953167 0.88 ALDH1A1 (0.34) ABCG2CYP1A1CYP1A2FYNMAPK3
SCHEMBL26740087 0.88 CHEK2 (0.38) AHRMAPTHPGDTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395263-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE LT MATERIALS CO., LTD. (KR) 2021-12-23 US disclosed
EP-3862353-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE LT Materials Co., Ltd. (KR) 2021-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395263-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE ODC1, AOX1, CYP1B1 ABCG2 2212/4885CYP1A1 4/4885CYP1A2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.